Daiichi Sankyo Co Ltd (4568):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(DATA904C7719)
◆英語タイトル:Daiichi Sankyo Co Ltd (4568) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C7719
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:64
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,125見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,375見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Daiichi Sankyo Co Ltd (4568) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Daiichi Sankyo Company Ltd (Daiichi Sankyo) is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrologic, diabetic, metabolic and infectious diseases; and various types of cancers. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

Daiichi Sankyo Co Ltd Key Recent Developments

Oct 09,2018 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of “Joinus”, a joint research program to discover new drugs using drug-repositioning compound library
Sep 24,2018 Daiichi Sankyo Presents Updated Results for Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer
Sep 21,2018 Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201
Sep 11,2018 TOPC : Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers[Newswire : Healthcare - PRN]

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Daiichi Sankyo Co Ltd – Key Facts 6
Daiichi Sankyo Co Ltd – Key Employees 7
Daiichi Sankyo Co Ltd – Key Employee Biographies 8
Daiichi Sankyo Co Ltd – Major Products and Services 9
Daiichi Sankyo Co Ltd – History 10
Daiichi Sankyo Co Ltd – Company Statement 21
Daiichi Sankyo Co Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Joint Venture 25
Section 2 – Company Analysis 26
Company Overview 26
Daiichi Sankyo Co Ltd – Business Description 27
Product Category: Generic Business 27
Overview 27
Performance 27
Product Category: Innovative Pharmaceuticals Business 27
Overview 27
Performance 28
Product Category: OTC Related Business 28
Overview 28
Performance 28
Product Category: Others 28
Performance 28
Performance 28
Product Category: Vaccine Business 29
Overview 29
Performance 29
Product Category: Healthcare (OTC) Products 29
Overview 29
Performance 29
Product Category: Others 29
Performance 29
Performance 29
Product Category: Prescription drugs 30
Overview 30
Performance 30
Geographical Segment: Europe 30
Performance 30
Geographical Segment: Japan 30
Performance 30
Geographical Segment: North America 30
Performance 30
Geographical Segment: Other Regions 30
Performance 30
R&D Overview 30
Daiichi Sankyo Co Ltd – Corporate Strategy 32
Daiichi Sankyo Co Ltd – SWOT Analysis 33
SWOT Analysis – Overview 33
Daiichi Sankyo Co Ltd – Strengths 33
Daiichi Sankyo Co Ltd – Weaknesses 34
Daiichi Sankyo Co Ltd – Opportunities 35
Daiichi Sankyo Co Ltd – Threats 36
Daiichi Sankyo Co Ltd – Key Competitors 37
Section 3 – Company Financial Ratios 38
Financial Ratios – Capital Market Ratios 38
Financial Ratios – Annual Ratios 39
Performance Chart 42
Financial Performance 42
Financial Ratios – Interim Ratios 43
Financial Ratios – Ratio Charts 44
Section 4 – Company’s Lifesciences Financial Deals and Alliances 45
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 45
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 46
Daiichi Sankyo Co Ltd, Recent Deals Summary 47
Section 5 – Company’s Recent Developments 48
Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of “Joinus”, a joint research program to discover new drugs using drug-repositioning compound library 48
Sep 24, 2018: Daiichi Sankyo Presents Updated Results for Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer 49
Sep 24, 2018: Daiichi Sankyo Presents Updated Results for Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer 51
Sep 21, 2018: Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201 53
Sep 21, 2018: Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201 54
Sep 11, 2018: TOPC : Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers[Newswire : Healthcare - PRN] 55
Sep 11, 2018: TOPC : Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers[Newswire : Healthcare - PRN] 56
Sep 11, 2018: TOPC : Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers[Newswire : Healthcare - PRN] 57
Aug 29, 2018: ProLynx and Daiichi Sankyo announce the development of technology for half-life extension of small molecules in the eye 58
Aug 28, 2018: Daiichi Sankyo Presents First Snapshot Analyses from Global ETNA-AF Programme of Oral, Once-daily LIXIANA (edoxaban) in Patients with Nonvalvular Atrial Fibrillation in Routine Clinical Practice 59
Section 6 – Appendix 60
Methodology 60
Ratio Definitions 60
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Daiichi Sankyo Co Ltd, Key Facts 6
Daiichi Sankyo Co Ltd, Key Employees 7
Daiichi Sankyo Co Ltd, Key Employee Biographies 8
Daiichi Sankyo Co Ltd, Major Products and Services 9
Daiichi Sankyo Co Ltd, History 10
Daiichi Sankyo Co Ltd, Subsidiaries 22
Daiichi Sankyo Co Ltd, Joint Venture 25
Daiichi Sankyo Co Ltd, Key Competitors 37
Daiichi Sankyo Co Ltd, Ratios based on current share price 38
Daiichi Sankyo Co Ltd, Annual Ratios 39
Daiichi Sankyo Co Ltd, Annual Ratios (Cont...1) 40
Daiichi Sankyo Co Ltd, Annual Ratios (Cont...2) 41
Daiichi Sankyo Co Ltd, Interim Ratios 43
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 45
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 46
Daiichi Sankyo Co Ltd, Recent Deals Summary 47
Currency Codes 60
Capital Market Ratios 60
Equity Ratios 61
Profitability Ratios 61
Cost Ratios 62
Liquidity Ratios 62
Leverage Ratios 63
Efficiency Ratios 63

List of Figures
Daiichi Sankyo Co Ltd, Performance Chart (2014 - 2018) 42
Daiichi Sankyo Co Ltd, Ratio Charts 44
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 45
Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 46

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Daiichi Sankyo Co Ltd (4568):企業の財務・戦略的SWOT分析(Daiichi Sankyo Co Ltd (4568) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆